[1] Packham DK,Alves TP,Dwyer JP,et al.Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy:results from the DIAMETRIC(Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database[J].Am J Kidney Dis,2012,59(1):75-83.
[2] Miyata T,Izuhara Y.Inhibition of advanced glycation end products:an implicit goal in clinical medicine for the treatment of diabetic nephropathy [J].Ann N Y Acad Sci,2008,1126:141-146.
[3] Huang P,Zhang Y,Jiang T,et al.Role of aldose reductase in the high glucose induced expression of fibronectin in human mesangial cells[J].Mol Biol Rep,2010,37(6):3017-3021.
[4] Geraides P.Activation of protein kinase C isofoms and its impact on betidiacom plieation[J].Circ Res,2010,30(4):1319-1322.
[5] 冯俊,肖新莉,刘哲,等.转化生长因子β1与内皮素转换酶-1b基因多态性和颈动脉粥样硬化易感性的关联研究[J].中华神经医学杂志,2011,10(9):879-882.
[6] Chawla T,Sharma D,Singh A.Role of the renin angiotensin system in diabetic nephropathy[J].World J Diabetes,2010,1(5):141-145.
[7] 陶凯.氯沙坦对糖尿病大鼠肾脏的保护作用[J].实用医学杂志,2012,28(20):3354-3355.
[8] Wang L,Zhang Y,Chen S,et al.Association of metabolic syndrome and IgA nephropathy[J].J Clin Pathol,2010,63(8):697-701.
[9] Van Buren PN,Toto R.Hypertension in diabetic nephropathy:epidemiology,mechanisms,and management[J].Adv Chronic Kidney Dis,2011,18(1):28-41.
[10] Mancia G.Effects of intensive blood pressure control in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes(ACCORD) trial[J].Circulation,2010,122(8):847-849.
[11] Moin S,Gondal GM,Bano U.Risk of development of chronic kidney disease in patients with type 2 diabetes having metabolic syndrome[J].J Coll Physicians Surg Pak,2008,18(8):472-476.
[12] Zoppini G,Targher G,Chonchol M,et al.Higher HDL cholesterol levels are associated with alower incidence of chronic kidney disease in patients with type 2 diabetes[J].Nutr Metab Cardiovasc Dis,2009,19(8):580-586.